Ninety One SA PTY Ltd Has $1.84 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ninety One SA PTY Ltd increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,457 shares of the company’s stock after purchasing an additional 341 shares during the quarter. Ninety One SA PTY Ltd’s holdings in IDEXX Laboratories were worth $1,843,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC raised its position in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $37,000. Finally, Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter worth $31,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $465.03 on Wednesday. The company has a fifty day moving average price of $424.92 and a 200 day moving average price of $453.54. The firm has a market cap of $38.08 billion, a PE ratio of 44.84, a PEG ratio of 3.64 and a beta of 1.37. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.18% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Stifel Nicolaus cut their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.